top of page
News, Events and Updates
Search
Neuroprotective efficacy of ANAVEX 2-73, a novel tetrahydrofuran derivative targeting the sigma-1...
Sep 11, 2010
Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/σ1 ligand ANAVEX 2-73
Sep 9, 2010
Anavex to Present at Rodman & Renshaw Healthcare Conference September 13 in New York City
Sep 8, 2010
Dr. Cameron Durrant Named One of PharmaVOICE’s 100 Most Inspiring in the Pharmaceutical Industry
Aug 30, 2010
Anavex Appoints Contract Research Organizations to Initiate Phase I/IIa Clinical Programs
Aug 10, 2010
Anavex Reports Animal Study Results as Lead Alzheimer’s Compound Approaches Phase 1 Clinical Trials
May 4, 2010
Anavex Comments on Failure of Pfizer and Medivation’s Dimebon
Mar 3, 2010
Anavex Appoints Dr. Cameron Durrant Executive Chairman of the Board
Jan 18, 2010
Anavex Contracts FORENAP Pharma for Pre-Clinical Trials of ANAVEX 2-73 in Alzheimer's Disease
Sep 30, 2009
Anavex Completes Scale-Up Manufacturing of ANAVEX 2-73 for Phase I AD Clinical Trials
Sep 21, 2009
Anavex Reports Sigma Receptor Review Published in Leading Journal
Aug 27, 2009
45
46
47
48
49
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
